Angeles Wealth Management LLC Acquires Shares of 1,682 Repligen Corporation $RGEN

Key Points

• Angeles Wealth Management LLC has acquired 1,682 shares of Repligen Corporation, worth approximately $209,000, indicating increased institutional interest in the biotechnology company.
• Repligen's quarterly revenue increased by 14.8% year-over-year, reporting $182.37 million, though they missed earnings per share estimates by $0.03.
• Analyst ratings for Repligen are mixed, with one analyst issuing a Strong Buy and ten issuing Buy ratings, while the average price target stands at $169.62.

Angeles Wealth Management LLC acquired a new stake in Repligen Corporation (NASDAQ:RGEN - Free Report) in the 2nd quarter, according to its most recent disclosure with the SEC. The fund acquired 1,682 shares of the biotechnology company's stock, valued at approximately $209,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Alliance Wealth Advisors LLC UT raised its holdings in Repligen by 2.5% in the 1st quarter. Alliance Wealth Advisors LLC UT now owns 3,675 shares of the biotechnology company's stock valued at $468,000 after acquiring an additional 89 shares in the last quarter. State of Michigan Retirement System increased its stake in shares of Repligen by 0.8% in the 1st quarter. State of Michigan Retirement System now owns 12,453 shares of the biotechnology company's stock valued at $1,585,000 after purchasing an additional 100 shares during the last quarter. Louisiana State Employees Retirement System increased its stake in shares of Repligen by 0.7% in the 1st quarter. Louisiana State Employees Retirement System now owns 14,600 shares of the biotechnology company's stock valued at $1,858,000 after purchasing an additional 100 shares during the last quarter. State of Wyoming increased its stake in shares of Repligen by 5.2% in the 1st quarter. State of Wyoming now owns 2,338 shares of the biotechnology company's stock valued at $297,000 after purchasing an additional 115 shares during the last quarter. Finally, Signaturefd LLC increased its stake in shares of Repligen by 65.3% in the 1st quarter. Signaturefd LLC now owns 324 shares of the biotechnology company's stock valued at $41,000 after purchasing an additional 128 shares during the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Repligen

In related news, Director Martin D. Madaus purchased 1,800 shares of Repligen stock in a transaction on Friday, August 8th. The shares were purchased at an average price of $112.13 per share, for a total transaction of $201,834.00. Following the transaction, the director owned 1,800 shares of the company's stock, valued at approximately $201,834. This represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Company insiders own 1.20% of the company's stock.

Analyst Ratings Changes

Several brokerages have recently issued reports on RGEN. Wall Street Zen lowered Repligen from a "buy" rating to a "hold" rating in a research note on Sunday. HSBC began coverage on Repligen in a research note on Wednesday, October 1st. They issued a "buy" rating and a $150.00 price target on the stock. Evercore ISI lifted their price target on Repligen from $155.00 to $175.00 and gave the company an "outperform" rating in a research note on Tuesday, October 7th. Royal Bank Of Canada reiterated an "outperform" rating and issued a $205.00 price target on shares of Repligen in a research note on Tuesday, September 2nd. Finally, Stephens upgraded Repligen to an "overweight" rating and set a $160.00 price objective on the stock in a research report on Tuesday, July 22nd. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, Repligen has an average rating of "Moderate Buy" and an average price target of $169.62.

Repligen Trading Down 1.3%

Shares of RGEN stock opened at $152.60 on Friday. The firm has a market capitalization of $8.59 billion, a P/E ratio of -610.38, a P/E/G ratio of 2.82 and a beta of 1.08. Repligen Corporation has a twelve month low of $102.96 and a twelve month high of $182.52. The company has a quick ratio of 7.32, a current ratio of 8.59 and a debt-to-equity ratio of 0.26. The stock's fifty day simple moving average is $128.81 and its 200 day simple moving average is $126.29.

Repligen (NASDAQ:RGEN - Get Free Report) last issued its quarterly earnings data on Tuesday, July 29th. The biotechnology company reported $0.37 earnings per share for the quarter, missing analysts' consensus estimates of $0.40 by ($0.03). Repligen had a positive return on equity of 4.61% and a negative net margin of 2.05%.The firm had revenue of $182.37 million for the quarter, compared to the consensus estimate of $174.62 million. During the same quarter in the prior year, the firm earned $0.40 EPS. The company's revenue was up 14.8% on a year-over-year basis. Repligen has set its FY 2025 guidance at 1.650-1.720 EPS. As a group, sell-side analysts predict that Repligen Corporation will post 1.72 EPS for the current fiscal year.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Corporation (NASDAQ:RGEN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.